StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Total cash, cash equivalents & current investments by Quarter

Total cash, cash equivalents & current investments ($M) ($M)

QuarterlyAnnual

AstraZeneca Total cash, cash equivalents & current investments: $4,968M in Q2 2026, down 30.1% from a year earlier.

Latest, Q2 2026
4,968
Period ended Jun 30, 2026
Change on a year earlier
-30.1%
7,108 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Cash and investments | 4,968 | 5,741 | 7,108”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Net Debt Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal cash, cash equivalents & current investments ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20264,968-30.1%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20267,675+42.3%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20255,741+1.5%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 20258,182+66.0%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 20257,108+0.5%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20255,395-32.7%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 20245,654-5.2%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 20244,930-3.6%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 20247,076+21.7%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 20248,021+24.1%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20235,962-6.9%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20235,115+4.4%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20235,812+18.9%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20236,462+11.0%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20226,405+0.1%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20224,898-31.5%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up total cash, cash equivalents & current investments

Cite this data

StockData. (2026). AstraZeneca Total cash, cash equivalents & current investments ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/nd-total-cash

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.